503A vs 503B
Two compounding pathways — patient-specific pharmacy vs cGMP outsourcing facility.
What a comparison is not
A comparison is SPEQ’s reading of how two published documents differ. Neither is the right answer, it is not a determination of which applies to you, and neither is summarised in a way that replaces reading it.
Sections 503A and 503B of the US Federal Food, Drug, and Cosmetic Act define two compounding pathways. A 503A pharmacy compounds patient-specific preparations pursuant to a prescription, regulated primarily by state boards of pharmacy. A 503B outsourcing facility registers with the FDA, compounds larger volumes (often without patient-specific prescriptions), and must follow cGMP. The choice determines who regulates you and how heavy the requirements are.
| ASPECT | 503A | 503B |
|---|---|---|
| Primary regulator | State board of pharmacy (FDA for select provisions) | FDA (registers as an outsourcing facility) |
| Prescription basis | Patient-specific prescription required | May compound without patient-specific prescriptions (office stock) |
| GMP | USP <795>/<797>/<800>; not full cGMP | Full cGMP compliance required |
| Scale | Limited, patient-by-patient | Larger batches for healthcare facilities |
| FDA inspection | Not routinely, absent for-cause | Routine, risk-based FDA inspection |
| Adverse-event reporting | Per state requirements | FDA adverse-event reporting required |
Operate under 503A when you compound patient-specific preparations against individual prescriptions — your primary regulator is your state board, and USP <795>/<797>/<800> govern practice.
Register as a 503B outsourcing facility when you compound at scale (e.g., office stock for hospitals) — you accept full cGMP and routine FDA inspection in exchange for compounding without patient-specific prescriptions.
The dividing line is patient-specific pharmacy practice (503A, state-regulated, USP chapters) vs cGMP manufacturing-grade compounding at scale (503B, FDA-registered and inspected). The framing error that matters: for a 503A pharmacy the primary regulator is the state board, not the FDA — and USP chapters acquire legal force through state adoption by reference. 503B exists so hospitals can buy compounded office stock made under cGMP.
503A vs 503B: frequently asked questions
Common questions on how 503A and 503B differ and when each applies.
Who regulates a 503A pharmacy?
Primarily the state board of pharmacy where it operates; the FDA retains authority over certain provisions. USP <795>, <797>, and <800> govern practice and acquire legal force through state adoption by reference. This is different from a 503B facility, which registers with and is inspected by the FDA.
Does a 503B facility have to follow cGMP?
Yes. Registering as a 503B outsourcing facility means accepting full current Good Manufacturing Practice compliance and routine, risk-based FDA inspection — in exchange for being able to compound larger volumes without patient-specific prescriptions.
Can a 503A pharmacy compound office stock?
Generally no. 503A compounding is tied to patient-specific prescriptions. Compounding non-patient-specific “office stock” for healthcare providers is the domain of a 503B outsourcing facility.
Is one safer than the other?
Neither is inherently “safer,” but 503B’s cGMP requirements and FDA oversight impose a higher, manufacturing-grade control standard suited to larger-volume production, whereas 503A relies on USP compounding standards and state oversight for patient-specific preparation.